CA
NZ
UK
AU
IND
US
…
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -78.05M | -28.60M | -5.75M |
| Net income | -148.88M | -28.82M | -6.09M |
| Selling general administrative | 18.14M | 3.94M | 1.37M |
| Selling and marketing expenses | 3.75M | 0.71M | 0.01M |
| Gross profit | 97.50M | - | - |
| Reconciled depreciation | 0.07M | 0.01M | 0.00M |
| Ebit | -67.56M | -29.83M | -5.43M |
| Ebitda | -6.88M | -29.81M | -5.43M |
| Depreciation and amortization | 60.68M | 0.01M | 0.00M |
| Operating income | -67.56M | -29.83M | -5.43M |
| Other operating expenses | 104.46M | 29.84M | 5.43M |
| Interest expense | 0.27M | 0.22M | 0.34M |
| Tax provision | 0.00M | 0.00M | 0.00M |
| Interest income | 0.01M | 0.01M | 0.00M |
| Net interest income | -0.26M | -0.21M | -0.34M |
| Income tax expense | 70.83M | 0.22M | 0.34M |
| Total revenue | 97.50M | 0.00M | 0.00M |
| Total operating expenses | 104.46M | 29.84M | 5.43M |
| Total other income expense net | -10.49M | 1.23M | -0.32M |
| Net income from continuing ops | -78.05M | -28.60M | -5.75M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 347.10M | 531.58M | 59.78M | 9.23M |
| Intangible assets | 0.17M | - | - | - |
| Other current assets | 6.34M | - | - | - |
| Total liab | 58.70M | 47.06M | 9.99M | 12.81M |
| Total stockholder equity | 288.39M | 484.52M | 49.79M | -3.58M |
| Other current liab | 23.97M | 11.28M | 0.00M | 0.76M |
| Common stock | 10.17M | 599.19M | 83.88M | 2.50M |
| Capital stock | 10.17M | 599.19M | 83.88M | 2.50M |
| Retained earnings | -316.97M | -119.36M | -34.68M | -6.08M |
| Cash | 340.45M | 438.52M | 53.09M | 7.86M |
| Total current liabilities | 49.90M | 35.46M | 9.88M | 12.81M |
| Current deferred revenue | 8.94M | 13.01M | 3.61M | - |
| Net debt | -340.39M | -438.40M | -52.93M | 3.79M |
| Short term debt | 0.06M | 0.06M | 0.05M | 11.65M |
| Short long term debt | - | - | - | 11.65M |
| Short long term debt total | 0.06M | 0.12M | 0.16M | 11.65M |
| Other stockholder equity | 273.80M | - | - | - |
| Total current assets | 346.79M | 448.13M | 58.87M | 9.22M |
| Net receivables | 1.88M | 1.94M | 4.29M | - |
| Inventory | -1.88M | - | - | - |
| Accounts payable | 16.92M | 11.11M | 6.22M | 0.40M |
| Accumulated other comprehensive income | 4.42M | 4.69M | 0.59M | - |
| Non currrent assets other | 0.04M | 0.15M | 0.72M | - |
| Non current assets total | 0.31M | 83.45M | 0.91M | 0.01M |
| Capital lease obligations | 0.06M | 0.12M | 0.16M | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 0.71M | -0.02M | -0.01M |
| Total cash from financing activities | 375.18M | 68.99M | 11.32M |
| Net income | -78.05M | -28.60M | -5.75M |
| Change in cash | 385.43M | 45.23M | 5.36M |
| Begin period cash flow | 53.09M | 7.86M | 2.50M |
| End period cash flow | 438.52M | 53.09M | 7.86M |
| Total cash from operating activities | 7.97M | -25.16M | -5.97M |
| Issuance of capital stock | 377.78M | 69.00M | 0.00M |
| Depreciation | 0.07M | 0.01M | 0.00M |
| Other cashflows from financing activities | -2.53M | -0.02M | -0.01M |
| Capital expenditures | 0.01M | 0.02M | 0.01M |
| Change in working capital | 11.46M | 3.82M | -0.53M |
| Stock based compensation | 3.92M | 1.05M | 0.00M |
| Other non cash items | 70.57M | -0.01M | 0.31M |
| Free cash flow | 7.96M | -25.18M | -5.98M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| NAMSW NewAmsterdam Pharma Company N.V. Warrant |
0.73 8.90% |
8.98 | - | - | - | - |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facc., Facp., M.D. | CEO, Pres, Exec. Board Member & Director | 1957 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer & Member of Exec. Board | 1954 |
| Ms. Louise Kooij | CFO, Treasurer, Member of Exec. Board & Director | NA |
| Mr. Douglas F. Kling | COO, VP & Director | 1973 |
| Mr. Jim Jacobson | Chief Legal Officer & Sec. | NA |
| Ms. Lina Gugucheva | Chief Bus. Officer | NA |
| Dr. Sheng Cui Ph.D. | VP & Head of Chemistry Manufacturing and Controls (CMC) | NA |
| Ms. Annie Neild | VP & Head of Regulatory Affairs | NA |
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President, Executive Board Member & Director | 1956 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 1954 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...